🧬 “The vaccine produced helps protect individuals against diseases and related cancers.” Merck, 63A West Point Facility $MRK $NWBO $IBRX That’s not a generic statement. It’s a quiet blueprint. Because in three Mayo Clinic trials, Merck’s own vaccines weren’t used to prevent cancer, they were injected into tumors alongside dendritic cell vaccines to treat it. These weren’t theoretical experiments. They were full-phase human trials using a validated M7-style DC platform: Autologous monocyte-derived DCs, matured ex vivo, and injected into cryoablated tumor tissue. 🔁 Mayo’s Human Trials: DC Vaccines Merck Adjuvants = Immune Ignition 📌 Melanoma Trial (NCT03325101) – Stage III–IV PD-1–resistant melanoma – Cryoablation intratumoral DC vaccine Prevnar13 – Followed by systemic pembrolizumab – Goal: reignite exhausted T-cell responses via innate priming 📌 B-cell Lymphoma Trial (NCT01239875) – Arm A: Cryo intratumoral DC vaccine Pneumovax 23 – Arm B: DC–tumor lysate fusion vaccine, delivered intradermally – Immune endpoints included T-cell activation, myeloid suppression, response durability 📌 Refractory NHL Trial (NCT03035331) – Cryoablation intratumoral DC vaccine Prevnar13 – Layered with pembrolizumab systemically – Protocol tracked PD-L1 modulation, antigen spreading, and systemic regression Same DC vaccine design. Same Merck vaccine payloads. Same tumor injection strategy. This wasn’t prevention. It was immune reprogramming. 🏭 Merck’s 63A Plant: Scaled Manufacturing for Immune Activation Merck now operates a facility that can produce 70 million pre-filled vaccine syringes per year They say these vaccines “protect against diseases and related cancers” Mayo showed that same vaccine (when injected into cryo-treated tumors) can: •Reignite antigen-presenting cell activation •Drive T-cell expansion against tumor neoantigens •Amplify dendritic cell therapy outcomes •Function as an adjuvantized immune ignition switch And now it can be manufactured at industrial scale 🧠 Strategic Map: Merck × Mayo × DCVax Merck controls: ✔️ Prevnar13, Pneumovax 23 (used as therapeutic primers) ✔️ Pembrolizumab (used in 2 of 3 trials) ✔️ West Point 63A (scalable vaccine output) ✔️ The human trial precedent (via Mayo) NWBO controls: ✔️ Autologous dendritic cell manufacturing IP ✔️ Flaskworks automation for scale-out ✔️ UK export infrastructure and SI 87 access pathway ✔️ A Phase I–validated platform (DCVax-Direct) ready for plug-and-play adjuvants What’s been proven in clinic is now reproducible in supply chain 🧩 Bottom Line Merck isn’t just making vaccines. They’re building a modular immune ignition system, one already proven in combination with DC vaccines. Same payloads. Same tumors. Same immune strategy. Now scaled. And one platform away from deployment. #DCVax #Merck #MayoClinic #CheckpointCombo #DendriticCells #Flaskworks #CancerVaccines #ImmuneStack #Oncology $NWBO $MRK $IBRX